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Progesterone stimulates G2-arrested Xenopus oocytes to synthesize Mos, a MAPK kinase kinase required for the coordinated activation of
cdc2 and the G2/Meiosis I (MI) transition. Mos leads to activation of MAPK, Rsk, and the inhibition of the cdc2 inhibitor Myt1. Previous work
identified CK2h as a Mos-interacting protein, and suggested that CK2h acts as a negative regulator by setting a threshold above which newly
made Mos must accumulate to activate MAPK. However, it had not been demonstrated that CK2h directly inhibits Mos. We report here that
Mos (52–115) is required for CK2h binding and can serve as a portable binding domain. To test whether CK2h acts at the level of Mos or on a
downstream component, we took advantage of previous work that showed injection of Mos arrests rapidly dividing embryonic cells. We find
that coinjection of CK2h and Mos into embryonic cells inhibits the ability of Mos to arrest cell division. In contrast, CK2h does not inhibit the
mitotic arrest induced by injection of active Rsk. These results argue that CK2h directly binds and inhibits Mos rather than a downstream
component, and support that CK2h functions as a molecular buffer that prevents premature MAPK activation and oocyte maturation.
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Studies of the molecular mechanisms of oocyte matura-
tion in Xenopus laevis have contributed much to our under-
standing of cell cycle regulation in both meiosis and mitosis
in all eukaryotes. Immature stage VI oocytes in the ovary are
arrested in G2 (prophase) of meiosis I, with the germinal
vesicle (nucleus) intact, chromatin partially condensed, and
cdc2 inactive (reviewed in Ferrell, 1999; Nebreda and Ferby,
2000). Progesterone activates two parallel cytoplasmic sig-
naling pathways that then converge to activate cdc2/cyclin
B, required for G2/M transition (Fig. 1). One branch leads to
the activation of cdc25, the phosphatase that removes the
inhibitory phosphorylations on cdc2. The other branch leads
to the translation of the mRNA encoding Mos, a serine/
threonine MAPK kinase kinase that, in turn, leads to the
inhibition of Myt1, the kinase that adds the inhibitory
phosphorylations to cdc2. Activated cdc2/cyclin B initiates0012-1606/$ - see front matter D 2004 Published by Elsevier Inc.
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E-mail address: ruderman@hms.harvard.edu (J.V. Ruderman).oocyte maturation (Fig. 1). The oocyte then enters M phase,
undergoes GVBD (germinal vesicle breakdown), completes
meiosis I, and proceeds directly into meiosis II. Oocyte
maturation is complete when the oocyte (now called an egg)
arrests in metaphase of meiosis II, ready for fertilization
(Ferrell, 1999; Maller, 1998; Sagata, 1997).
Activation of Mos and the MAPK pathway is a key event
in oocyte maturation. Mos was identified as a newly made M
phase inducer (Sagata et al., 1988) that activates preexisting
stores of MEK and MAPK (Nebreda and Hunt, 1993; Posada
et al., 1993; Shibuya and Ruderman, 1993). Little was
known about upstream Mos regulators. Using a yeast two-
hybrid screen with Mos as bait, the noncatalytic beta subunit
of the kinase CK2 (CK2h) was identified as a potential
interacting protein (Chen et al., 1997). Interaction of Mos
and CK2hwas seen in several different systems, including in
vitro binding assays, cotransfection into 293T cells, and in
oocytes overexpressing CK2h. In vitro, CK2h can inhibit
Mos kinase activity, as incubating v-Mos (a constitutively
active Mos) with GST-CK2h resulted in a 40% decrease in
GST-MKK phosphorylation (Chen et al., 1997). While
injection of CK2h inhibits progesterone-stimulated oocyte
maturation and reduces sensitivity to progesterone, antisense
to CK2h accelerates oocyte maturation, and lowers the dose
Fig. 1. Progesterone stimulates oocyte maturation through two parallel
pathways. Mos is sufficient to activate MAPK and induce the G2/MI
transition and oocyte maturation. CK2h, a negative regulator of oocyte
maturation, potentially functions by inhibiting Mos. (Not all feedback loops
and interactions shown.)
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MAPK activation (Chen and Cooper, 1997; Chen et al.,
1997). Furthermore, CK2h also inhibits maturation in the
oocytes of the closely related Xenopus tropicalis (Stanford et
al., 2003). Thus, CK2h can act as a negative regulator of
progesterone-stimulated oocyte maturation.
These results suggested that CK2h, which is already
present in G2-arrested oocytes, sets a threshold level above
which newly made Mos protein must accumulate before it
can phosphorylate MEK and activate MAPK. Activation of
the Mos-MEK-MAPK cascade generates a positive feed-
back loop, leading to the further synthesis and accumulation
of Mos (Howard et al., 1999), which in turn contributes to
the all-or-nothing manner of MAPK activation that is seen
following progesterone stimulation (Ferrell, 1996; Ferrell
and Machleder, 1998). The presence of a threshold level of
CK2h in the oocyte would prevent low ‘‘noise’’ levels of
Mos translation from prematurely activating the MAPK
pathway. Furthermore, an inhibitor of Mos such as CK2h
would contribute to generating a switch-like activity and
irreversibly commit the oocyte to enter meiosis I and
undergo maturation (Chen et al., 1997; Ferrell, 1996).
However, neither evidence of a binding site on Mos nordirect interaction of endogenous CK2h and Mos in vivo has
been demonstrated.
In this report, we identify a novel CK2h-binding domain
within the N-terminus of Mos, which matches closely the
known CK2h binding site on CK2a, the catalytic subunit of
the CK2 holoenzyme. This domain is a dominant, portable
domain capable of docking an unrelated protein, cyclin A, to
CK2h. We also provide evidence that in vivo, CK2h
inhibits signaling at the level of Mos itself, and not
downstream of Mos-mediated MAPK. These results further
support the idea that maternal stores of CK2h directly bind
and inhibit Mos, thus providing a buffer that protects
oocytes from activation without a mitogenic signal.Materials and methods
Constructs
The full-length X. laevis Mos cDNA pXenMos, a gift of
Angus MacNicol (University of Arkansas for Medical
Sciences) (MacNicol et al., 1997), was subcloned into the
vector pCS2+ between the ClaI and XbaI sites. Mos
truncations were made using PCR primers and subcloned
into the pCS2+ vector at the EcoRI and XhoI sites. Mos/
Xenopus cyclin A2 fusion proteins were created by using
PCR primers to add a XhoI site to the 5V end of cyclin A,
omitting the first methionine, and a 3V XbaI site. The cyclin
A PCR product was subcloned into various pCS2+ vectors
containing different truncations of Mos, at the XhoI/XbaI
sites, C-terminal to Mos. The human CK2h constructs
pCS3+CK2h and pGEX2T-CK2h were a gift of Jonathan
Cooper (University of Washington) (Chen et al., 1997). The
Xenopus Rsk construct, pCRII-Xp90Rsk, was a gift of
Angel Nebreda (European Molecular Biology Laboratories)
(Palmer et al., 1998) and subcloned into the pCS2+ vector.
Constitutively active Xenopus p90Rsk (CA-Rsk) was creat-
ed using PCR primers to amino acids 45 through 390, as
published in Gross et al. (1999) and subcloned into the
pCS2+HA vector, a gift of Ethan Lee (Harvard Medical
School). All constructs were verified by DNA sequencing.
In vitro transcription/translation
DNA templates were linearized by digestion with appro-
priate restriction enzymes, extracted with phenol/chloro-
form, ethanol precipitated, and transcribed in vitro using
the mMessage mMachine kit (Ambion). The resulting
mRNAs were treated with DNase and precipitated with
lithium chloride. mRNAs were resuspended in nuclease free
H2O, aliquoted and frozen at 80jC.
Making GST and GST-CK2b proteins
BL21 competent cells were transformed with either
pGEX2T vector (Pharmacia Biotech) or pGEX2T-CK2h.
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and Speicher, 1997). Briefly, overnight cultures were diluted
1:20 into 600 ml of LB containing 100 Ag/ml ampicillin and
grown at 37jC until an OD between 0.5–0.7. Bacteria were
induced to express protein using 1 mM IPTG (isopropyl-1-
thio-h-D-galacto-pyranoside, Sigma I-6758), and grown at
37jC for 3 h. Bacteria were pelleted at 5000  g for 20 min
at 4jC and frozen at 80jC. The pellet was resuspended in
15 ml of ice-cold freshly prepared lysis buffer [50 mM
NaCl, 50 mM Tris pH 8.0, 5 mM EDTA, 0.15 mM PMSF,
1Complete protease inhibitor tablet (Roche)] and sonicat-
ed. Samples were centrifuged at 18,000  g for 20 min at
4jC. Supernatants were removed to new tubes, and 0.4 ml
of glutathione sepharose (Amersham Biosciences 17-0756-
01) was added. Samples were incubated at 4jC overnight.
Proteins were batch purified. Briefly, proteins were centri-
fuged at 500  g for 5 min at 4jC, and washed twice with
buffer 1 [1 PBS pH 7.4 (NaCl 137 mM, KCl 2.7 mM,
Na2HPO4 10 mM, KH2PO4 1.7 mM), 5 mM EDTA, 0.15
mM PMSF] followed by two washes with buffer 2 (1 PBS
pH 7.4, 5 mM EDTA). Proteins were eluted using 10 mM
reduced glutathione (Sigma G-4251) in 50 mM Tris adjust-
ed to pH 8.0. Protein concentration was quantified using the
Lowry assay and confirmed by Western blotting. Proteins
were aliquoted and stored at 80jC.
In vitro binding assay
PCR products were subcloned into the pCS2+ vector and
in vitro transcribed and translated in rabbit reticulocyte
lysate, incubating with 35S-cysteine (Promega TnT coupled
reticulocyte lysate systems). The in vitro binding assay was
adapted from one used by Chen et al. (1997). Equimolar
amounts of 35S-labeled Xenopus Mos protein were incubat-
ed with 2 Ag of bacterially expressed GST-CK2h protein or
with GST alone in 500 Al of ice-cold Binding Buffer (10
mM HEPES pH 7.5, 2 mM EDTA, 150 mM NaCl, 50 mM
NaF, 0.1% h-mercaptoethanol, 1 mM aprotinin, 1 mM
PMSF) and incubated for 2 h at 4jC. Mos proteins that
bound to GST-CK2h were pulled down using glutathione
sepharose and incubated for 1 h at 4jC. Complexes were
washed three times, first with high salt Binding Buffer
(NaCl increased to 700 mM) followed by two washes with
ice-cold Binding Buffer. Bound proteins were eluted by
boiling for 5 min in 1SDS loading buffer (125 mM Tris
pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue,
5% h-mercaptoethanol), and analyzed by SDS-PAGE, fol-
lowed by autoradiography. Half of the input was loaded into
the load lanes. Binding was quantified by phosphorimager
exposure for all results.
Injections into Xenopus two-cell embryos
X. laevis females were primed with 50 U PMSG (Preg-
nant Mare Serum Gonadotropin) at least 3 days before
injection with 500 U hCG (human chorionic gonadotropin,Sigma CG-10) to induce egg laying overnight at 16jC.
Freshly squeezed eggs were fertilized using macerated testes
and then dejellied in 2% cysteine pH 8.0. Dejellied eggs were
rinsed twice in 0.25MMR solution (100 mM NaCl, 2 mM
KCl, 1 mM MgCl2, 2 mM CaCl2, 0.1 mM EDTA, 5 mM
HEPES pH 7.8) and then transferred to 3% Ficoll (Sigma F-
4375) in 0.25MMR. Embryos were allowed to develop
until the two-cell stage. One blastomere of a two-cell embryo
was injected with either mRNA alone or with a combination
of mRNA and protein. Injected embryos developed at 22jC
until 7 h postfertilization and were visually scored for
blastomere arrest. At least 30 embryos were injected with
Mos mRNA alone or with Mos and GST, and at least 80
embryos were coinjected with Mos and GST-CK2h per
experiment. The results from four independent experiments
were graphed with calculated standard deviations.
Immunoblotting
Embryos were homogenized in 10 Al/embryo of ice-cold
homogenization buffer (65 mM Tris pH 7.5, 10 mM EGTA,
10 Ag/ml PMSF, 1Complete protease inhibitor) by passage
through a pipette tip. Samples were centrifuged at 10,000 
g for 10 min at 4jC. The cytoplasmic portion was removed
to fresh tubes containing 4SDS loading buffer. The
equivalent of one embryo was loaded per lane. Samples
were separated by gel electrophoresis as previously de-
scribed (Anderson et al., 1973; Laemmli, 1970) and trans-
ferred to nitrocellulose. Blots were incubated in specific
blocking solutions (see below) for 1 h, incubated in primary
antibody from 1 h to overnight, washed 3 with TBST (50
mM Tris, 150 mM NaCl, 1% Tween-20), incubated in
secondary antibody for 1 h, washed 3 with TBST, and
then visualized by chemiluminescence (ECL, Amersham).
All primary and secondary antibodies were prepared in
TBST. For a-Mos antibodies (JVR) (custom made to a N-
terminus sequence in Xenopus Mos), blots were blocked
with 5% milk, primary antibody was diluted 1:1000 in 2%
milk, and secondary antibody was sheep-a-rabbit diluted
1:5000 in 2% milk. For a-HA antibodies (Boehringer
Mannheim #1583816), blots were blocked with 5% milk,
primary antibody was diluted 1:1000 in 2% milk, and
secondary antibody was sheep-a-mouse diluted 1:5000 in
2% milk. For a-GST antibodies (Z-5, Santa Cruz #sc-459),
blots were blocked with 5% milk, primary antibody was
diluted 1:1000 in 2% milk, and secondary antibody was
sheep-a-rabbit diluted 1:5000 in 2% milk.Results
The N-terminus half of Mos is necessary for strong binding
to GST-CK2b
To test for the presence of a discrete CK2h-binding
domain in Mos, a series of Mos N- and C-terminal trunca-
Fig. 2. The N-terminus half of Mos is required for strong binding to CK2h. (A) The catalytic domain of Xenopus Mos (shaded) is divided into 12 subdomains
as marked. (B) Summary of truncated Mos constructs and binding to GST-CK2h. (C) C-terminal and (D) N-terminal truncated Mos cDNAs were in vitro
transcribed and translated in rabbit reticulocyte lysate and labeled using 35S-cysteine. Translation product was incubated with 2 Ag of bacterially expressed GST
or GST-CK2h and purified using glutathione sepharose. Binding of 35S-labeled proteins was analyzed by SDS-PAGE and detected by autoradiography. The
Mos (164–359) construct contained a N-terminal myc tag.
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made as close as possible to the natural boundaries of
individual subdomains within the catalytic domain. Mos
and CK2h interaction was tested using an in vitro binding
assay similar to that used by Chen et al. (1997). Briefly,
equimolar amounts of 35S-labeled Xenopus Mos translation
product prepared in rabbit reticulocyte were incubated with
bacterially expressed GST or GST-CK2h protein, and com-
plexes which bound to GST were isolated using glutathione
sepharose. After several washes, bound proteins were eluted
and detected by gel electrophoresis followed by autoradi-
ography (Fig. 2C). Binding between full-length wild-type
Mos and GST-CK2h was readily detected by this approach,
where typically 7–12% of the total input of Mos protein
was bound by GST-CK2h, as quantified by phosphorimager
analysis (Fig. 2C and data not shown). Very low background
interaction of Mos with GST was seen. Deletion of up to
100 amino acids from the C-terminus of Mos (constructs 1–
4, Fig. 2B) did not disrupt strong binding to GST-CK2h
(Fig. 2C), suggesting that the C-terminal 100 amino acids of
Mos are not required for binding to CK2h. Further deletion
of the C-terminus, Mos (1–183), and Mos (1–164) de-
creased binding to GST-CK2h slightly. On the other hand,
all constructs lacking the N-terminal half, starting with Mos
(164–359) (Fig. 2B, constructs 7–9), showed less than 1%
binding (Fig. 2D), indicating that the N-terminal half of Mos
is required for strong binding to CK2h.
Mos (52–115) contains a CK2b-binding domain
To identify the region of Mos that is sufficient for CK2h
binding, we tested consecutively smaller truncations of theMos N-terminus. However, Mos truncations smaller than
14 kDa co-migrated with reticulocyte lysate globin proteins,
and thus could not be scored for binding (data not shown),
precluding this approach. We thus made the Mos truncation
constructs larger by fusing them to Xenopus cyclin A2
(cycA), which by itself does not bind to GST or GST-CK2h
(Fig. 3B), and mapped the CK2h-binding domain in Mos
by using truncated Mos/cycA fusion proteins (Fig. 3A).
Fusion of Mos (1–335) to cycA was able to confer CK2h
binding to cycA (Fig. 3C). The fivefold increase of binding
of CK2h over background levels (phosphorimager data not
shown) demonstrates that cycA fusion to the C-terminus of
Mos did not interfere with the GST-CK2h binding to Mos.
Mos (1–115)/cycA bound to GST-CK2h as well as the
Mos (1–335)/cycA fusion protein (Fig. 3C). Removal of
additional residues from the Mos C-terminus resulted in
decreased binding, as Mos (1–102)/cycA bound less well
than Mos 1–115/cycA (4% vs. 6% binding, respectively).
Mos (1–78)/cycA showed no binding to CK2h over
background GST levels (Fig. 3C). This result suggests that
Mos (1–115) contains the CK2h-binding domain.
Deletions beginning from the Mos N-terminus revealed
that Mos (52–115)/cycA bound to CK2h as well as Mos
(1–115)/cycA. Binding dropped sharply from 14% to 3%
when 10 more amino acids were removed from the N-
terminus in Mos (62–115). Thus, the residues from 52–115
of Mos contains the CK2h-binding domain (Fig. 3C). Mos
(52–115) includes noncatalytic residues (52–62), as well as
subdomains I to III (63–115) of the catalytic domain,
known to be important for ATP binding and orientation.
The crystal structure of CK2h bound to the catalytic subunit
CK2a (Niefind et al., 2001) reveals this exact region of
Fig. 3. Mos (52–115) is a portable CK2h-binding domain and confers binding to cyclin A. (A) Summary of Mos truncation proteins fused to full-length
Xenopus cyclin A2 and binding to GST-CK2h. (B) Wild-type Mos and cyclin A cDNAwas in vitro transcribed and translated in rabbit reticulocyte lysate and
labeled using 35S-cysteine. Translation product was incubated with 2 Ag of bacterially expressed GST or GST-CK2h and purified using glutathione sepharose.
Binding of 35S-labeled proteins was analyzed by SDS-PAGE and detected by autoradiography. (C) Mos fusion proteins (A) were tested for binding to GST-
CK2h as described in B. (D) Comparison of CK2h binding regions (hatched) on Mos and CK2a. The beginning of the catalytic domains (shaded) of Mos and
CK2a are aligned.
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CK2h binding region in Mos, which matches this CK2a
region almost exactly, strongly supports the idea that CK2h
exerts its effects by binding to Mos directly in vivo.
CK2b inhibits the ability of Mos to arrest embryonic cells in
mitosis
To test whether CK2h could inhibit Mos function in
vivo, we turned to the well-established blastomere arrest
assay (Masui and Markert, 1971; Sagata et al., 1989). This
assay provided an excellent opportunity to ask if CK2h
inhibits activation of this pathway at the level of Mos and/or
at the level of downstream signaling proteins. In Xenopus
oocytes, Mos is required to establish arrest in metaphase of
meiosis II. Shortly after fertilization, Mos is degraded as the
zygote enters interphase of the first mitotic cycle (reviewed
in Sagata, 1997; Tunquist and Maller, 2003). Injection of
Mos mRNA into one blastomere of a two-cell embryo is
sufficient to induce blastomere arrest, while the uninjectedblastomere continues to divide normally (Sagata et al.,
1989). While endogenous Mos protein levels are extremely
low or absent in the two cell embryo, all of the downstream
pathway components required to establish and maintain the
arrest are present, including MEK, MAPK, and p90Rsk.
Injection of Mos mRNA translates into active Mos protein,
and activates these components to generate mitotic arrest
(reviewed in Tunquist and Maller, 2003).
To rule out the possibility that overexpressing CK2h
itself affected the early embryonic cell cycles, one blasto-
mere of a two-cell embryo was injected with increasing
amounts of bacterially expressed GST or GST-CK2h pro-
tein. No visible effect on the morphology or the rate of cell
division was seen in blastomeres injected with up to 60 AM
of GST-CK2h (data not shown). Next, to determine the
lowest concentration of Mos mRNA needed to arrest 100%
of blastomeres by the eight-cell stage, increasing amounts of
Mos mRNA were injected into blastomeres and scored for
the cell stage at which blastomeres arrested. Injection of 1
ng of Mos mRNA routinely arrested 100% of blastomeres
Fig. 4. CK2h inhibits Mos-induced mitotic arrest in embryonic cells. (A)
Indicated amounts of Mos mRNA were injected into one blastomere of a
two-cell embryo, and scored 7 h postfertilization for the stage at which
blastomeres arrested. (B) Blastomeres were injected with 1 ng Mos mRNA
or coinjected with 42 AM of either GST or GST-CK2h protein. Embryos
were lysed and samples were Western blotted with anti-Mos (top) and anti-
GST (bottom) antibodies to confirm expression. (C) Injected embryos in B
were scored for blastomere arrest as in A.
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subsequent experiments (Fig. 4A).
We then asked whether CK2h could interfere with the
ability of Mos to arrest cell division. Mos mRNA was
coinjected with either GST or GST-CK2h protein, so that
as soon as Mos is translated into protein, CK2h was
available for binding. A mixture of Mos mRNA and GST-
CK2h protein was injected into single blastomeres of two-
cell embryos. Embryos were allowed to develop until 7
h postfertilization and then scored for the stage at which
blastomeres arrest. Expression levels of Mos and GST-
CK2h were confirmed by Western blots (Fig. 4B). The
weaker detection of GST-CK2h may have to do with
epitope detection, as equimolar amounts of protein were
injected. As expected, endogenous Mos was detected in the
unfertilized egg, but not in the uninjected embryo 7 h post
fertilization. The majority of the blastomeres injected with
Mos arrested at the four-cell stage, and all had arrested by
the eight-cell stage (Fig. 4C). Coinjection of GST with Mos
yielded a similar arrest profile. In contrast, when Mos and
GST-CK2h were coinjected, the majority of the injected
blastomeres arrested at the eight-cell stage. Furthermore, in
many cases, blastomeres were seen that arrested even later,
at the 16 and 32/64 cell stages, along with some that had no
visible arrest at all. Taken together, these findings demon-
strate that CK2h antagonizes Mos-induced arrest in blasto-
meres, and strongly suggest that CK2h can specifically
regulate components of the Mos signaling pathway in
oocytes.
CK2b does not inhibit Rsk-induced CSF arrest
To determine whether the effect of CK2h is at the level
of Mos or downstream, we asked whether CK2h would
antagonize CSF arrest induced by injecting p90Rsk, a
kinase downstream of Mos. Previous work showed that
constitutively active Rsk (CA-Rsk), consisting of a portion
of the N-terminus kinase of p90Rsk (residues 45–390),
induces a CSF arrest that appears identical to that induced
by Mos, yet does not activate endogenous MAPK or Rsk,
removing potential complications with feedback loops
(Gross et al., 1999). HA-tagged CA-Rsk mRNA was
injected alone or coinjected with GST or GST-CK2h protein
into one blastomere of two-cell embryos. Embryos were
allowed to develop for 7 h and then scored for the stages at
which blastomeres arrested. As above, Western blots con-
firmed the presence of CA-Rsk expression and the presence
of injected GST or GST-CK2h (Fig. 5A). Injecting Rsk
mRNA alone arrested 33% of blastomeres at the eight-cell
stage, and about 50% of blastomeres at the 16-cell stage
(Fig. 5B). Blastomeres coinjected with Rsk and GST protein
showed 40% of blastomeres arrested at the eight-cell stage,
and 38% of blastomeres arrested at the 16-cell stage. The
arrest profile for blastomeres coinjected with both Rsk and
GST-CK2h was similar to those injected with Rsk and GST,
as the percentage of blastomeres arrested at the 8- and 16-
Fig. 5. CK2h does not inhibit Rsk-induced arrest. (A) 13.5 ng HA-tagged
constitutively active CA-Rsk mRNA was injected alone and with either 42
AM of GST or GST-CK2h protein. Injected embryos were lysed and
samples were Western blotted with anti-HA (top) or anti-GST (bottom)
antibodies to confirm expression. (B) Embryos were injected as in A and
scored 7 h postfertilization for the cell stage at which blastomeres were
arrested.
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calculated standard deviation. These results indicate that
CK2h does not inhibit Rsk-induced blastomere arrest.
Given that CK2h can inhibit the more potent Mos-induced
arrest, the inability of CK2h to inhibit Rsk-induced arrest
strongly supports the idea that CK2h does not act at the
level of Rsk or a component downstream of Rsk. The
experiments presented here, together with the result that
MKK (human MEK) does not interact with CK2h in a yeast
two hybrid assay (Chen et al., 1997), provide compelling
evidence that CK2h inhibits at the level of Mos in vivo.Discussion
The work described here establishes three main points.
(i) A small region (52–115) in the N-terminus of Mos,
which has both noncatalytic residues and catalytic subdo-mains I–III, contains the binding site recognized by CK2h.
This region is required for the ability of Mos to bind CK2h,
and is sufficient to confer CK2h binding to a protein which
by itself does not interact, cyclin A. (ii) In addition to CK2h
interfering with the ability of Mos to promote the G2/M
transition in Xenopus oocytes, CK2h can also inhibit the
ability of Mos to arrest rapidly dividing embryonic cells.
(iii) CK2h fails to inhibit the action of Rsk, a downstream
component of the Mos/MAPK pathway, arguing that the
major inhibitory effect of CK2h is through binding to Mos,
and not downstream components.
Increasing evidence suggests that CK2h has functions
independent of the regulation of the CK2a catalytic subunit
and formation of the CK2 holoenzyme (Allende and
Allende, 1995; reviewed in Litchfield, 2003). Free popula-
tions of CK2h without CK2a have been identified in mouse
testis and brain (Guerra et al., 1999). Also, CK2h and CK2a
are found present in different subcellular localizations, and
exhibit independent nuclear import and export (Filhol et al.,
2003). Once thought to be an extremely stable and irrevers-
ible complex, the crystal structure of CK2 is consistent with
the idea that holoenzyme formation is transient (Niefind et
al., 2001). Furthermore, CK2h has been reported to interact
with at least 30 different partners in various yeast two-
hybrid screens (Boldyreff and Issinger, 1997; Chen et al.,
1997; Grein et al., 1999; Hagemann et al., 1997; Kusk et al.,
1999).
The CK2h-binding domain of Mos closely matches the
identified CK2h-binding domain on CK2a, as defined by
crystal structure (Niefind et al., 2001). This further argues
that the region identified in Mos is the relevant binding site.
This CK2h-binding domain in Mos contains the highly
conserved ATP binding loop, which acts as a flexible clamp
that anchors the nontransferable phosphates of ATP (Hardie
and Hanks, 1995). Thus, CK2h binding to this region might
block efficient ATP binding, explaining how CK2h inhibits
Mos kinase activity (Chen et al., 1997). Secondly, this
region contains the so-called ‘‘Mos box’’ (Mos 51–66),
which consists mostly of noncatalytic sequences (Okazaki et
al., 1991). This sequence is highly conserved between
Xenopus, mouse and human Mos, and is critical for Mos
kinase activity, its ability to induce mitotic arrest, and the
ability of Mos to transform cells (Okazaki et al., 1991). One
possibility is that the Mos box is responsible for the
selectivity of CK2h binding to Mos, which distinguishes
Mos from other serine/threonine kinases. Comparison of the
primary amino acid sequences of CK2a and Mos does not
reveal any obvious consensus residues when compared
against kinases reported not to bind to CK2h (MKK1, B-
raf, C-raf) (Boldyreff and Issinger, 1997; Chen et al., 1997;
Hagemann et al., 1997). Taken together, these findings
argue that CK2h inhibits Mos directly, rather than inhibiting
Mos synthesis or promoting its degradation.
Intriguingly, in contrast to its inhibitory effect on Mos,
association of CK2h with certain other kinases, such as
Chk1 and A-raf, has been reported to increase kinase
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the CK2 holoenzyme, CK2h binding increases the substrate
specificity and the overall activity of the CK2a catalytic
subunit moderately in most studies. However, binding of
CK2h to CK2a can also inhibit CK2 phosphorylation of
certain substrates, and appears to depend in part on the
identity of the substrate and the sequences surrounding the
phosphoacceptor site (Bidwai et al., 1993; Meggio et al.,
1992). Thus, CK2h binding appears to act more like a
modulator of activity than as an on/off switch.
The regulation of Mos by CK2h in some ways resembles
that seen for the regulation of Raf by RKIP (Raf Kinase
Inhibitor Protein) (Yeung et al., 1999, 2000). RKIP has been
proposed to set the sensitivity threshold for the Raf/MAPK
pathway, both to suppress background signals and to
strongly amplify signals exceeding a threshold. Interesting-
ly, RKIP binding also maps to subdomains I/II of the
catalytic domain of Raf-1 (Yeung et al., 2000). And like
CK2h, RKIP can also interact with other kinases, including
NF-nB-inducing kinase (Yeung et al., 2001). Thus, by
acting as molecular buffers against inappropriate kinase
activation, CK2h and RKIP provide an additional mecha-
nism for regulating cell fate decisions.Acknowledgments
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